JUN 17, 2015 08:00 AM PDT
Real-Time Profiling of Tumor Heterogeneity in Metastatic Disease
SPONSORED BY: Epic Sciences
15 37 10034

Speakers:
  • VP of Translational Research, Epic Sciences
    Biography
      Mark Landers has 20 years of experience developing and commercializing molecular assays to drive translational and clinical research. In his current position as VP of Translational Research at Epic Sciences, he is leading the development of assay's to characterize CTC by genotype and phenotype at the single cell level. These assays can be utilized to develop clinical tests to drive patient care decisions. Prior to his tenure at Epic Sciences, Mark was Head of R&D at AltheaDx where he developed several companion assays for targeted therapies. He has also held several senior level scientist positions in the San Diego biotech community, at companies including LifeTechnologies, Ceregene and Vical.

    Abstract:
    DATE: June 17th, 2015
    TIME: 8am Pacific time, 11am Eastern time

    Spatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized with targeted PET imaging, biopsy IHC and microdissected-targeted NGS. Tissue biopsies can underestimate clonal and phenotypic differences between metastatic sites, and lack of single cell characterization can homogenize intra-tumoral heterogeneity. Additionally, acquired therapeutic resistance leads to temporal heterogeneity of tumors leading to the need for longitudinal tissue biopsies in some patients. Recently, large investments into liquid biopsies have employed the utilization of cfDNA to identify tumor mutations with known targets or are correlated with resistance to disease. However, utilization of cfDNA as a primary tool can underestimate intra-patient tumor heterogeneity and neglect the protein drivers of disease progression, including tyrosine kinase receptor amplification, loss of tumor suppressor function, epithelial plasticity. At Epic Sciences, we have developed a platform to characterize single circulating tumor cells (CTCs) for morphologic, protein and genomic targets at the single cell level and have applied the platform to thousands of samples from metastatic cancer patients. We will present data on the impact of morphology, protein chemistry and genomics of single CTCs in the context of contemporary unmet clinical needs in mCRPC. The impact of this clinical data suggests employment of a rational development of combination therapies to combat disease heterogeneity.

    Show Resources
    Loading Comments...